Shares of InTest Corporation jumped 7.3% to $13.20 in early trading Friday after the small-cap test-equipment maker delivered a third quarter that topped Wall Street expectations across the board — raising a pointed question about whether the stock's rally, already up 61% over the past year, has more room to run.

  • An Earnings Beat That Doubled Analyst Expectations. InTest reported adjusted EPS of $0.18, beating the analyst estimate of $0.10 by $0.08.

Revenue of $35.1 million edged past consensus of $34.8 million.

Gross margin hit 47.7%, with gross profit up 52% year over year — a sign that the company is selling a richer mix of higher-margin products, not just shipping more boxes. Net earnings swung to $1.9 million from a loss of $0.9 million a year ago, while adjusted EBITDA surged to $4.4 million from just $0.4 million. For a company with a $164 million market cap, that kind of profitability improvement matters.

  • Record Orders Signal Demand Is Accelerating, Not Plateauing. Orders hit a record $49.4 million, up 31% year over year, led by record back-end semiconductor orders. The book-to-bill ratio — new orders divided by revenue shipped — was above 1.3x, meaning the order pipeline is growing faster than the company can ship. Backlog reached $59.7 million, up roughly 32% from $45.4 million at the end of Q2. That backlog provides revenue visibility well into 2027, a rare luxury for a company this size.

  • Guidance Holds Steady — The Real Payoff May Come Next Year. Management guided Q4 revenue of $34 million to $36 million, roughly in line with the $35.22 million consensus. The cautious guidance reflects that much of the bulging backlog won't convert to revenue until 2027. For shareholders, this means the earnings inflection is likely still in early innings.

  • Diversification Cushions the Chip-Cycle Risk. In Q1, 69% of revenue came from non-semiconductor markets — defense, auto/EV, life sciences, and industrial. That spread reduces dependence on the notoriously cyclical chip sector. Three analysts rate the stock a "Strong Buy" with an average price target of $20, implying 52% upside from today's price. The gap between today's price and that target reflects both the opportunity and the skepticism that a sub-$200M company can sustain double-digit growth.